Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma-Reference-Cited by-同舟云学术

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Author:

Ito Yasuhiro¹,Onoda Naoyoshi²,Ito Ken-ichi³,Sugitani Iwao⁴,Takahashi Shunji⁵,Yamaguchi Iku⁶,Kabu Koki⁷,Tsukada Katsuya⁸

Affiliation:

1. Clinical Trial Management Center, Kuma Hospital, Kobe, Japan.

2. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.

3. Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

4. Department of Endocrine Surgery II, Nippon Medical School, Tokyo, Japan.

5. Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

6. Product Development, Clinical Statistics, Bayer Yakuhin Ltd., Osaka, Japan.

7. Medical Affairs/KI Oncology, Bayer Yakuhin Ltd., Tokyo, Japan.

8. Medical Affairs, Oncology and Hematology, and Clinical Development, Specialty Medicine, Bayer Yakuhin Ltd., Tokyo, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

Reference20 articles.

3. Union for International Cancer Control 2009 TNM Classification of Malignant Tumors. Seventh edition. Wiley-Blackwell, Hoboken, NJ.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献